TruAlt Bioenergy Other Announcement
TruAlt Bioenergy filed Crisil's monitoring agency report for the quarter ended 30 September 2026 on its Rs 750 crore IPO proceeds. The report notes no deviation from the IPO objects.
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
8 announcements with these filters
TruAlt Bioenergy filed Crisil's monitoring agency report for the quarter ended 30 September 2026 on its Rs 750 crore IPO proceeds. The report notes no deviation from the IPO objects.
TruAlt reported massive 606% YoY revenue growth, turning profitable despite raw material price surges. Management is pivoting from ethanol to high-margin CBG to insulate from feedstock volatility.
Q2 FY27 consolidated total income ₹823.74 Cr, PAT ₹34.99 Cr, EBITDA margin 12.47%. H1 PAT ₹94.27 Cr, EBITDA ₹233.92 Cr (16.27% margin). Strategy: integrated bioenergy across ethanol, CBG, SAF, retail.
TruAlt Bioenergy reported H1 FY27 revenue of ₹1,437.98 crore, EBITDA of ₹233.92 crore and PAT of ₹94.27 crore via press release. Results reverse last year's H1 loss.
TruAlt Bioenergy Ltd reported revenue from operations of ₹811.1 Cr (+605.9% YoY) and net profit of ₹35 Cr for Q2 FY27.
Mr. Monu Kumar resigned as Company Secretary and Compliance Officer of TruAlt Bioenergy Limited, effective October 16, 2026, due to personal reasons.
The company submitted its quarterly shareholding pattern for the period ended September 30, 2026, as required by regulatory compliance.
TruAlt Bioenergy announced a board meeting on October 23, 2026, to consider and approve unaudited financial results for the quarter and half-year ended September 30, 2026.